Lexaria Begins New Nicotine Formulation Creation and Evaluation Program

Rhea-AI Summary

Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) has entered into agreements with Altria to provide DehydraTECH powder-based nicotine formulations for evaluation. These agreements will be effective until March 31, 2023. Lexaria's DehydraTECH technology enhances the bio-absorption of active pharmaceutical ingredients, improving oral delivery by 5-10 times and reducing onset times from 1-2 hours to minutes. The company holds 24 patents and has over 50 pending worldwide. For further details, visit Lexaria's website.

Positive

• Agreements with Altria enhance credibility and potential revenue sources.
• DehydraTECH technology shows ability to significantly improve drug delivery effectiveness.

Negative

• None.

KELOWNA, BC / ACCESSWIRE / April 11, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has entered new agreements with Altria Client Services, LLC ("Altria").

Under the terms of these agreements, Lexaria will receive a fee to provide certain DehydraTECH powder-based nicotine formulations to be evaluated by Altria. The new agreements are in effect until March 31, 2023.

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 24 patents granted and over 50 patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:

George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.

View source version on accesswire.com:
https://www.accesswire.com/696886/Lexaria-Begins-New-Nicotine-Formulation-Creation-and-Evaluation-Program

FAQ

What are the details of Lexaria's agreement with Altria dated April 11, 2022?

Lexaria Bioscience Corp. has entered agreements with Altria to provide DehydraTECH powder-based nicotine formulations for evaluation, effective until March 31, 2023.

What is DehydraTECH technology and its benefits?

DehydraTECH technology improves the oral delivery of active pharmaceutical ingredients, increasing bio-absorption by 5-10 times and reducing time of onset from 1-2 hours to minutes.

How many patents does Lexaria hold?

Lexaria holds 24 granted patents and has over 50 patents pending worldwide regarding its DehydraTECH technology.

What is the stock symbol for Lexaria Bioscience Corp.?

The stock symbols for Lexaria Bioscience Corp. are LEXX and LEXXW.